Wednesday, February 8, 2023 | Back issues
Courthouse News Service Courthouse News Service

Pharmaceutical Merger

Shareholders claim in a federal class action that key details are omitted from the Jan. 19 solicitation statement filed with the Securities and Exchange Commission concerning Takeda’s proposed $5.2 billion acquisition of Ariad Pharmaceuticals.

BOSTON – Shareholders claim in a federal class action that key details are omitted from the Jan. 19 solicitation statement filed with the Securities and Exchange Commission concerning Takeda’s proposed $5.2 billion acquisition of Ariad Pharmaceuticals.

Read the Top 8

Sign up for the Top 8, a roundup of the day's top stories delivered directly to your inbox Monday through Friday.

Loading
Loading...